World Heart Day 2022
World Heart Day 2022
World Heart Day 2022
World Heart Day – Raising awareness of Cardiovascular Diseases
On 29th September, World Heart Day is an opportunity for everyone to stop and consider how best to use heart for humanity, for nature, and for yourself. Beating cardiovascular disease is something that matters to every beating heart.
In May 2012, world leaders committed to reducing global mortality from non-communicable diseases (NCDs) by 25% by 2025. Cardiovascular disease (CVD) is accountable for nearly half of all NCD deaths making it the world’s number one killer. World Heart Day is, therefore, the perfect platform for the CVD community to unite in the fight against CVD and reduce the global disease burden.
World Heart Day is a global campaign created by the World Heart Federation in which it informs people around the globe that CVD, including heart disease and stroke, is the world’s leading cause of death claiming 18.6 million lives each year. It aims to highlight the actions that individuals can take to prevent and control CVD as well as to drive action to educate people by controlling risk factors such as tobacco use, unhealthy diet, and physical inactivity.
What are cardiovascular diseases?
Cardiovascular diseases (CVDs) are a group of disorders relating to the heart and blood vessels and they include:
- coronary heart disease – disease of the blood vessels supplying the heart muscle
- cerebrovascular disease – disease of the blood vessels supplying the brain
- peripheral arterial disease – disease of blood vessels supplying the arms and legs
- rheumatic heart disease – damage to the heart muscle and heart valves from rheumatic fever, caused by streptococcal bacteria
- congenital heart disease – malformations of heart structure existing at birth
- deep vein thrombosis and pulmonary embolism – blood clots in the leg veins, which can dislodge and move to the heart and lungs
How can Randox help with these current global challenges
Cardiovascular disease, including heart disease, is easier to treat when detected early. Here at Randox, we utilise innovative diagnostic tests for early risk assessment capable of diagnosing disease at the earliest possible stages, because we understand that “prevention is better than cure”.
Randox Laboratories is a world leader in innovative diagnostics with 40 years’ experience and a leading provider of diagnostic reagents for the assessment of cardiovascular disease risk. Randox offer an extensive menu of cardiac biomarkers within the cardiology reagents panel including:
Risk Assessment
- CK-MB – useful in patients with chest pain; Creatine Kinase is an enzyme produced in many different types of cells, of which high levels indicate muscle trauma or damage.
- Myoglobin – a small protein which leaks out of muscle cells after injury, is also considered a biomarker for the detection of Myocardinal Infraction.
- Routine lipid tests to determine the patient’s cholesterol and triglyceride levels – HDL Cholesterol, LDL Cholesterol, Total Cholesterol and Triglycerides
- Independent risk assessment tests such as sdLDL Cholesterol and Lipoprotein(a) to determine any genetic factors which may increase their risk of CVD. Please note, this is necessary even for patients who have good cholesterol levels
- Secondary tests, such as High Sensitivity CRP, in addition to risk assessment markers and lipid evaluation – secondary tests are important in predicting future cardiac events of individuals with no previous history of CVD and those deemed healthy because of primary tests; approximately half of all heart attacks occur in patients classified as low risk. In addition, they can also be used to evaluate the risk of a recurrent cardiac event
- Homocysteine – elevated levels of homocysteine have been linked to various disease states including CVD. Extremely high levels are found in patients with homocystinuria, of which many suffer from early arteriosclerosis.
More information
If you are a clinician or lab interested in our Cardiology & Lipids Panel, we have a wealth of resources available:
Download our Reagents Brochure
Download our Cardiology & Lipid Testing Brochure
If you would like to get in touch with a Sales representative please email us reagents@randox.com
Cardiac QC
Acusera Cardiac Controls is designed to deliver an assayed solution for Tropinin I and NT-proBNP testing. Its intended use with Roche, Abbott and Siemens. This control is manufactured using only the highest quality material and offers a 7-day thawed stability at +2ºC to +8ºC.
Four levels are available covering the clinically relevant range, including High Sensitivity Troponin I.
Features and Benefits
- Liquid for ease-of-use stability
- Aqueous material
- 4 Clinically relevant levels (including Ultra-Low)
- Stable to expiry date at -18-24ºC storage
- Thawed stability of 7 days at 2°C – 8°C
For more information, visit our Cardiac Quality Control website
If you have any other queries, don’t hesitate on contacting us at qualitycontrol@randox.com
Heart Health Test
High Cholesterol is a major risk factor for heart disease and stroke therefore at Randox Health we have the Heart Health Test to keep our cholesterol at a healthy level. This is done from the convenience of your home with our home sample collection kit. Heart Health measures your total cholesterol, HDL (good) cholesterol, LDL (bad cholesterol) and triglycerides.
Why we get tested?
There is so much importance in identifying cholesterol imbalance early which allows you to make appropriate dietary and lifestyle changes which in turn reduces your risk of heart disease and stroke. It is essential to acknowledge that regardless of your age and physical health, anyone can have high cholesterol; high levels may be a result of genetics or lifestyle which can often display with no underlying symptoms. Those with a family history of heart disease, who are overweight/ obese, drink alcohol, smoke regularly, lead a sedentary lifestyle or have diabetes are at an increased risk and should get tested.
Find out more here
Want to know more about Randox?
Contact us or visit our homepage to view more.
Celebrating World Hepatitis Day 2022!
Hepatitis is a condition that affects the liver and can be caused by an infection with a virus. With five different types of Hepatitis from A to E, the most common types of viral Hepatitis are A, B and C. These three viruses affect millions of people worldwide, causing both short-term illnesses and long-term liver disease.
World Hepatitis Day highlights the need to accelerate the fight against viral hepatitis and the importance of testing and treatment for those in need. The “I can’t wait” campaign brought to us by World Hepatitis Alliance, amplifies the voices of those affected demanding immediate action and the end of the stigma and discrimination attached.
Currently there are 325 million people who live with hepatitis globally with more than 1.1 million lives lost to hepatitis B and hepatitis C.
It is important to note that the use of appropriate quality control measures is vital in ensuring the appropriate daily performance of the assay used in the laboratory independent of the technology.
Features & Benefits of Randox Molecular Blood Borne Virus (BBV) Controls
- Traceable to International Standard (where available) or to Internal Reference Material
- Liquid frozen for user convenience and ease of use
- The panels are suitable for use with the majority of commercial and in-house molecular methods
- Manufactured to ISO: 13485 quality standards
Download brochure here
In addition to this, we have our third party Infectious Disease (Serology) Controls which are designed to deliver a cost-effective, high-quality solution for the analysis of infectious disease. Our controls are compatible for use on wide range of immunoassay platforms.
Features and Benefits
- Liquid ready to use – All samples are provided in a user-friendly, liquid ready-to-use format significantly reducing preparation time and the risk of pipetting errors.
- Commutability- Manufactured from human plasma each control is designed to react to the test system in the same manner as the patient sample, helping to meet ISO 15189:2012 requirements.
- True third-party controls – Designed to deliver an independent, unbiased assessment of performance with any instrument or method the Acusera range will help to meet ISO 15189:2012 requirements and eliminate the need for multiple instrument specific controls.
- Reduced waste – With a working stability of 60 days art 2oc to 8oC waste and costs are kept to a minimum.
- Consolidation – The availability of multi-marker controls will reduce the number of individual controls required ultimately reducing costs, time, and storage space.
- Clinically relevant – Designed to challenge clinically relevant ranges our low reactive samples will ensure accurate and reliable instrument performance.
- Acusera 24.7 – Our Acusera Infectious Disease (Serology) Controls are compatible for use with our interlaboratory data management software Acusera 24.7.
For more information about Third party Infectious Disease (Serology) Controls:
Visit our website: Serology Quality Controls
Or email: qualitycontrol@randox.com
Serology Control
Serology Brochure
Molecular IQC
Resource Hub
Anti-MĆ¼llerian Hormone (AMH) Quality Control
The Randox Acusera AMH control is designed for use as a third-party control for the quantitative determination of Anti-Müllerian Hormone (AMH). An AMH test is often used to check a woman’s ability to produce eggs that can be fertilized for pregnancy. Thus, helping women to make informed decisions about their health.
Available in a liquid frozen format, this control should be treated in the same manner as a patient sample.
Features & Benefits
- 30-day stability at +2°C to +8°C
- Liquid Frozen format for convenience and reduced handling errors
- True third-party control providing an unbiased assessment of performance
- Manufactured using human serum, ensuring commutable sample matrix
- Assayed target values provided eliminating the need to assign values in-house
- Control available at recommended cut-off values for AMH
| Description | Pack Size | Cat. Number | Typical Values Beckman DXL / Roche ng/ml | |
|---|---|---|---|---|
| AMH Control 1 | 3 x 2ml | AMH10509 | 0.5 | |
| AMH Control 2 | 3 x 2ml | AMH10514 | 1.0 | |
| AMH Control 3 | 3 x 2ml | AMH10515 | 6.0 | |
| AMH Control 4 | 3 x 2ml | AMH10516 | 16.0 |
Analyte
- Anti-Müllerian Hormone (AMH)
Serum Indices Quality Control
The Randox Acusera Serum Indices control is designed to be used to monitor an IVD instrument’s response in the detection of haemolyzed, icteric and lipemic (HIL) samples. This control can be utilised in laboratory interference testing to assist in improving error detection of pre-analytical errors affecting clinical chemistry testing.
This control provides a full range of clinically relevant testing levels, including a negative (-) and three positives (+, ++ & +++)
Features & Benefits
- Lyophilised for enhanced stability
- Manufactured using human serum, ensuring commutable sample matrix
- 2-year shelf life from date of manufacture
- True third party control providing unbiased assessment of performance
- Reconstituted stability of 14 days at 2°C – 8°C
- 4 separate levels available including -, +, ++ & +++
| Description | Size | Analytes | Cat No | |
|---|---|---|---|---|
| Serum Indices Control | 4 x 5 ml | 3 | SI10448 | |
Analytes
- Haemolysis (H)
- Icterus (I)
- Lipemia (L)
Cardiac Quality Control
Intended for use with Roche Abbott and Siemens systems, this control is manufactured using only the highest quality material and offers a 7-day thawed stability at +2ºC to +8ºC.
This control provides a full range of clinically relevant testing levels, including High Sensitivity Troponin I.
Features & Benefits
- Liquid Frozen
- Aqueous Material
- 4 Clinically relevant levels (including Ultra-Low)
- Stable to expiry date at -20ºC to -80ºC
- Thawed stability of 7 days at 2°C – 8°C
| Description | Optimised for | Size | Analytes | Cat No | |
|---|---|---|---|---|---|
| Cardiac Control - Ultra Low | Roche (NT proBNP) & Abbott (Troponin I) | 3 x 3 ml | 1 | CQ10453 | |
| Cardiac Control Ultra Low | Siemens | 6 x 1 ml | 2 | CQ10428 | |
| Cardiac Control Level 1 | Siemens | 6 x 1 ml | 2 | CQ10429 | |
| Cardiac Control Level 2 | Siemens | 6 x 1 ml | 2 | CQ10430 | |
| Cardiac Control Level 3 | Siemens | 6 x 1 ml | 2 | CQ10431 | |
Analytes
- Troponin I
- NT-proBNP
Neonatal Bilirubin External Quality Assessment
The RIQAS Neonatal Bilirubin EQA programme has been designed to assess the performance of total and direct bilirubin assays with levels tailored to neonatal bilirubin testing.
- Lyophilised for enhanced stability
- Monthly reporting
- Human based serum
- Submit results and view reports online via RIQAS.net
- Rapid turnaround of reports allows for any necessary corrective actions to be taken with minimal disruption to laboratory output
- Cycle Starts – July 2025
| Cat No | Kit Size | Frequency | Parameters | |
|---|---|---|---|---|
| RQ9191 | 2 x (6x3ml) | Monthly (1 x 12 month cycle) | 2 | |
Parameter
- Direct Bilirubin
- Total Bilirubin
Please note, product availability may vary country to country.
Liquid Bilirubin Control
Providing a true third party solution for the measurement of Bilirubin, the Acusera Liquid Bilirubin Control is designed to deliver an unbiased, independent assessment of analytical performance helping to ensure accurate and reliable patient testing.
Covering the required clinically relevant decision levels for neonatal testing of Direct and Total Bilirubin, with a 7 day open vial stability and 2 year shelf life the Acusera Liquid Bilirubin Control will reduce waste, whilst remaining easy and convenient to use.
Features & Benefits
- Liquid frozen
- 100% human serum
- 2 year shelf life from date of manufacture
- Clinically relevant decision levels, recommended by ISO15189
- Open vial stability of 7 days at 2°C – 8°C
- Assayed Control
- CE Marked
| Description | Size | Analytes | Cat No. | |
|---|---|---|---|---|
| Liquid Bilirubin Control | 3x3mL | Direct Bilirubin Total Bilirubin | BR10443 | |
Analytes
- Direct Bilirubin
- Total Bilirubin
Related Products
Randox Quality Control launches new Acusera D-Dimer Controls
Randox Quality Control launches new Acusera D-Dimer Controls
16 March 2021: Randox Quality Control launches new Acusera D-Dimer Controls
Randox Quality Control has launched a new range of Acusera Controls for the accurate and reliable testing of D-Dimer.
Providing a true third-party solution for D-Dimer testing, which is most often used to investigate whether a patient has a blood clotting disorder, this control is manufactured for use on a range of different diagnostic systems.
Designed to provide accurate and reliable patient testing, this control comes in a liquid frozen format and is stable for an impressive 28 days when stored at 2ºC to 8ºC.
Three levels are supplied, spanning the full clinical range and FEU.
Features and Benefits
- Liquid frozen
- 100% human serum
- 2 year shelf life from date of manufacture
- Cut-off level of 500 ng/ml (FEU) for most analysers
- Open vial stability of 28 days at 2°C – 8°C
- Assayed Control
For more information visit https://www.randox.com/d-dimer-internal-quality-control/
QUALITY CONTROL
REAGENTS
RX SERIES
SARS-CoV-2 (COVID-19) Antigen Testing Pilot Study from Randox Quality Control
SARS-CoV-2 (COVID-19) Antigen Testing Pilot Study
12 March 2020
SARS-CoV-2 (COVID-19) Antigen Testing Pilot Study
Randox, in partnership with QCMD, is pleased to announce a new QCMD EQA pilot study for SARS-CoV-2 (COVID-19) Antigen Testing. This new pilot is designed to evaluate a laboratory’s ability to detect SARS-CoV-2 (COVID-19) antigen and will provide an opportunity to assess performance against an international peer group.
QCMD is a world leading EQA / Proficiency Testing (PT) provider, dedicated to improving the quality of molecular diagnostic assays used in the detection of infectious diseases. With an extensive database of over 2000 participants in over 100 countries, QCMD is one of the largest providers of molecular EQA in the fi eld of infectious disease testing.
Features & Benefits
-
Whole PathogenAvailability of whole pathogen samples containing the entire viral genome, ensures commutability with the majority of commercial assays.
-
Smart-Phone App Results SubmissionResults can be returned via a smart-phone app so that participants using lateral flow devices can provide pictures of their device/result with the phone camera.
-
Comprehensive ReportsA real-time rapid report will be provided on submission of results. An individual report is received after each challenge, summarising laboratory performance in comparison to an international peer group.
-
EQA Management SystemIT EQA Management System (ITEMS) provides an online tool to easily manage all EQA activities from programme registration to submission of results and provision of EQA reports.
-
Not infectiousSamples containing SARS-CoV-2 antigens are inactivated and not infectious ensuring safe handling of material.
-
Suitable for Point of CareSamples are supplied liquid ready-to-use ensuring they are ideal for use at the point care.
For more information visit https://www.randox.com/qcmd-sars-antigen-testing/
For further enquiries please email marketing@randox.com
QCMD
QNOSTICS
CORONAVIRUS
Whole pathogen multiplex controls to support testing for cold, cough and COVID
27 October 2020
Whole pathogen multiplex controls to support testing for cold, cough and COVID
Just in time for flu season, global diagnostics company Randox Laboratories has unveiled a range of whole pathogen multiplex controls that cover multiple viral and bacterial pathogens which cause respiratory disease.
Inclusive of SARS-CoV-2, Influenza A & B, and Respiratory Syncytial Virus (RSV), the Qnostics Multiplex Respiratory Pathogen Controls (RTX) facilitate diagnosis of the likes of cold and flu, and importantly, the differentiation of these respiratory diseases from COVID-19.
Using a control line that covers a range of respiratory pathogens in this way will allow laboratories to streamline their testing, consolidate QC, and ultimately save time, money and resource.
Lynsey Adams, Randox Quality Control Manager, explained;
“When the use of time and resources are critical such as in COVID-19 testing, the use of highly characterised controls enables laboratories to meet their daily QC needs and accreditation requirements.
“Accurate and reliable laboratory testing is an essential aspect of the management of COVID-19 and other respiratory diseases, so we are pleased to be able to offer these new controls which will crucially support the validation, verification and performance monitoring of molecular respiratory assays.”
The new RTX controls, which are whole pathogen for compatibility with the majority of commercial and in-house assays, are used to monitor the full testing process, from extraction to amplification and detection.
The Multiplex Respiratory Controls will support public health testing strategies during the incoming flu season and are suited for the test menus of most syndromic assays.
Lynsey continued;
“The Randox Qnostics Multiplex Respiratory Pathogen Controls are clinically relevant for full-process validation. Liquid frozen for user convenience and ease of use, the development of the controls using whole pathogen material ensures clinical relevance from extraction to amplification and detection.”
Randox Qnostics Multiplex Respiratory Pathogen Controls are manufactured to ISO 13485 standards and are in line with ISO 15189:2012 regulatory requirements.
Key Features and Benefits of the new RTX Controls:
- Whole pathogen controls – the controls contain the entire genome meaning they are compatible with the majority of commercial and in-house assays.
- Full process control – whole pathogen controls are the ideal material for full-process validation, monitoring the testing process from extraction to amplification and detection, to ensure ultimate quality assurance in laboratories.
- Highly characterised – Qnostics controls are quantified by digital PCR to ensure batch to batch reproducibility and are traceable to an internal reference preparation, to ensure metrological traceability of test results obtained by different diagnostic workflows.
- True Third Party – An independent, unbiased assessment of assay performance is ensured in line with ISO 15189:2012 regulatory requirements.
- Superior Manufacturing – Qnostics controls are manufactured under ISO 13485 guidelines to ensure quality and traceability.
- Liquid for Ease-of-Use – the controls are conveniently supplied in a liquid frozen format meaning there is no additional preparation or handling required.
For more information visit https://www.randox.com/molecular-infectious-disease-controls/respiratory-infection-testing/
For further enquiries please email marketing@randox.com